APO MYC500
Pill imprint APO MYC500 has been identified as Mycophenolate mofetil 500 mg.
Mycophenolate mofetil is used in the treatment of organ transplant, rejection prophylaxis; nephrotic syndrome; inflammatory bowel disease; graft-versus-host disease; ulcerative colitis (and more), and belongs to the drug class selective immunosuppressants. There is positive evidence of human fetal risk during pregnancy.
Mycophenolate mofetil 500 mg is not subject to the Controlled Substances Act.
See also related documents.
Mycophenolate mofetil Images
- Imprint:
-
APO
MYC500 - Strength:
- 500 mg
- Color:
- Purple
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- Selective immunosuppressants
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- N - Not a controlled drug
- Manufacturer:
- Apotex Corp.
- National Drug Code (NDC):
- 60505-2967
Advertisement
More Mycophenolate Mofetil resources
- Mycophenolate Mofetil (Wolters Kluwer)
- Mycophenolate Mofetil Capsules (Wolters Kluwer)
- Mycophenolate Mofetil Solution (Wolters Kluwer)
- Mycophenolate Mofetil Suspension (Wolters Kluwer)
- mycophenolate mofetil (Cerner Multum)
- mycophenolate Intravenous (Micromedex) - Includes Dosage Information
- mycophenolate mofetil (Micromedex) - Includes Dosage Information
- mycophenolate mofetil Oral, Intravenous (Micromedex) - Includes Dosage Information
- Mycophenolate (AHFS DI)
- Mycophenolate (FDA)
- Mycophenolate Mofetil (FDA)
- Mycophenolate Tablets (FDA)
Mycophenolate Mofetil is associated with the treatment of:
- Autoimmune Hepatitis
- Bullous Pemphigoid
- Cogan's Syndrome
- Crohn's Disease
- Dermatomyositis
- Evan's Syndrome
- Graft-versus-host disease
- High Cholesterol
- Inflammatory Bowel Disease
- Multiple Sclerosis
- Myasthenia Gravis
- Nephrotic Syndrome
- Organ Transplant, Rejection Prophylaxis
- Pemphigoid
- Pemphigus
- Psoriatic Arthritis
- Pulmonary Fibrosis
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
- Ulcerative Colitis
- Uveitis
Search Again
